Effect of cerebrolysin on gross motor function of children with cerebral palsy: a clinical trial
- 221 Downloads
Gross motor dysfunction is considered as the most challenging problem in cerebral palsy (CP). It is proven that improvement of gross motor function could reduce CP-related disabilities and provide better quality of life in this group of patients. Therefore, the aim of this trial is to evaluate the effectiveness of cerebrolysin (CBL) on gross motor function of children with CP who are undergoing treatment. In this clinical trial study, paediatric patients aged 18–75 months with spastic diplegic or quadriplegic cerebral palsy, who were under rehabilitation therapy, were selected and randomly allocated in control and CBL groups. Patients in CBL group underwent treatment with standard rehabilitation therapy plus CBL. The latter was administrated intramuscularly as a single daily dose of 0.1 cc/kg for 10 days and then continued weekly for 4 months. Gross motor function of participants in the two studied groups, before and after trial, was evaluated and compared using the validated Persian version of gross motor function classification system-expanded and revised (GMFCS-E&R). During this trial, 108 patients with CP were evaluated for eligibility. From these, 50 patients were enrolled and randomly allocated in the CBL and control groups. Four months after trial, the mean level of GMFCS decreased significantly in the two groups (P < 0.05). However, it was significantly lower in the CBL group than in the control group (2.1 vs. 3.16, P < 0.05). The results of this trial indicated that CBL could improve gross motor function in patients with CP. This finding is consistent with neurotrophic and neuroprotective effects of CBL, which have been reported in various clinical trials in other neurological disorders. Further studies are recommended to establish the value of continued neuroprotection and to determine the pharmacokinetics/dynamics of CBL in this group of patients.
KeywordsCerebrolysin Cerebral palsy Motor
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
The protocol of the study was approved by the Pediatrics Review Board and the Regional Ethics Committee of Isfahan University of Medical Sciences (Research Project Number: 393470).
Written informed consent was obtained from the parents of selected patients after describing the goal of and treatments in the study.
- 1.Jones MW, Morgan E, Shelton JE, Thorogood C (2007) Cerebral palsy: introduction and diagnosis (part I). J Pediatr Health Care Off Publ Natl Assoc Pediatr Nurse Assoc Pract 21(3):146–152Google Scholar
- 5.Miller F (2005) Cerebral palsy. Springer Science-Business Media, New York, pp 523–666Google Scholar
- 7.Shamsoddini A, Amirsalari S, Hollisaz MT, Rahimnia A, Khatibi-Aghda A (2014) Management of spasticity in children with cerebral palsy. Iran. J Pediatr 24(4):345–351Google Scholar
- 10.Balakrishnan B, Nance E, Johnston MV, Kannan R, Kannan S (2013) Nanomedicine in cerebral palsy. Int J Nanomed 8:4183–4195Google Scholar
- 12.Alvarez XA, Cacabelos R, Laredo M, Couceiro V, Sampedro C, Varela M et al (2006) A 24-week, double-blind, placebo-controlled study of three dosages of cerebrolysin in patients with mild to moderate Alzheimer’s disease. Eur J Neurol Off J Eur Fed Neurol Soc 13(1):43–54Google Scholar
- 15.Zhang Y, Chopp M, Meng Y, Zhang ZG, Doppler E, Winter S et al (2015) Cerebrolysin improves cognitive performance in rats after mild traumatic brain injury. J Neurosurg 122(4):1–13Google Scholar
- 16.Masliah E, Diez-Tejedor E (2012) The pharmacology of neurotrophic treatment with cerebrolysin: brain protection and repair to counteract pathologies of acute and chronic neurological disorders. Drugs Today (Barc) 48(Suppl A):3–24Google Scholar
- 17.Chen N, Yang M, Guo J, Zhou M, Zhu C, He L (2013) Cerebrolysin for vascular dementia. Cochrane Database Syst Rev 1:CD008900Google Scholar
- 18.Alvarez XA, Cacabelos R, Sampedro C, Aleixandre M, Linares C, Granizo E et al (2011) Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer’s disease: results of a randomized, double-blind, controlled trial investigating three dosages of cerebrolysin. Eur J Neurol Off J Eur Fed Neurol Soc 18(1):59–68Google Scholar
- 20.Thome J, Doppler E (2012) Safety profile of cerebrolysin: clinical experience from dementia and stroke trials. Drugs Today (Barc) 48(Suppl A):63–69Google Scholar
- 21.Dehghan L, Dalvand H, Abdolvahab M, Bagheri H, Faghih zade S (2011) Inter rater reliability of Persian version Gross Motor Function Classification System Expanded & Revised in patients with cerebral palsy. Bimonthly Official Publication Medical Daneshvar 18(91):37–44Google Scholar
- 22.Sharma HS, Muresanu DF, Patnaik R, Stan AD, Vacaras V, Perju-Dumbrav L et al (2011) Superior neuroprotective effects of cerebrolysin in heat stroke following chronic intoxication of Cu or Ag engineered nanoparticles. A comparative study with other neuroprotective agents using biochemical and morphological approaches in the rat. J Nanosci Nanotechnol 11(9):7549–7569CrossRefPubMedGoogle Scholar
- 23.Young W (2009) Cerebrolysin Review. Available from https://wiseyoung.wordpress.com/2009/02/10/271/. Accessed 22 Dec 2016
- 24.Lukhanina EP, Karaban IN, Burenok Iu A, Mel’nik NA, Berezetskaia NM (2004) Zhurnal nevrologii i psikhiatrii imeni SS Korsakova/Ministerstvo zdravookhraneniia i meditsinskoi promyshlennosti Rossiiskoi Federatsii, Vserossiiskoe obshchestvo nevrologov [Effect of cerebrolysin on the electroencephalographic indices of brain activity in Parkinson’s disease] [i] Vserossiiskoe obshchestvo psikhiat 104(7):54–60Google Scholar
- 29.Allegri RF, Guekht A (2012) Cerebrolysin improves symptoms and delays progression in patients with Alzheimer’s disease and vascular dementia. Drugs Today (Barc) 48(Suppl A):25–41Google Scholar
- 30.Gershman RN, Vasilenko MA (1975) Use of cerebrolysin and ATP in treating infantile cerebral paralysis. Pediatr Akus Ginekol (1):22–23 (Article in Ukrainian)Google Scholar
- 31.Petrukhin AS, Pylaeva OA (2014) Cerebrolysin in pediatric neurology practice. Zh Nevrol Psikhiatr Im S S Korsakova 114(1 Pt 2):75–80 (Article in Russian)Google Scholar
- 32.Hong Z, Moessler H, Bornstein N, Brainin M, Heiss WD, Investigators C (2009) A double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of cerebrolysin in patients with acute ischaemic stroke in Asia–CASTA. Int J Stroke Off J Int Stroke Soc 4(5):406–412CrossRefGoogle Scholar